RBS analysts have gone the extra mile and put some in-depth analysis in place in an attempt to find out what really lies behind the horizon for Sonic. The result is some very encouraging signs and indications. Needless to say, RBS is confidently sticking with its Buy recommendation, in combination with a $12.19 price target.
You wouldn’t have noticed, but the above paragraph was written about two months ago. It still applies today, after another effort by RBS analysts to re-confirm their longer term positive view on Sonic’s prospects for the US market. No changes were made to forecasts.
Sector: Health Care Equipment & Services.
Target price is $12.19.Current Price is $11.02. Difference: $1.17 – (brackets indicate current price is over target). If SHL meets the RBS Australia target it will return approximately 10% (excluding dividends, fees and charges – negative figures indicate an expected loss).